Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment.
Obrecht-Sturm D, Schömig L, Mynarek M, Bison B, Schwarz R, Pietsch T, Pfister SM, Sill M, Sturm D, Sahm F, Kortmann RD, Gerber NU, von Bueren AO, Fleischhack G, Schüller U, Nussbaumer G, Benesch M, Rutkowski S. Obrecht-Sturm D, et al. Among authors: von bueren ao. Neuro Oncol. 2024 Sep 5;26(9):1712-1722. doi: 10.1093/neuonc/noae071. Neuro Oncol. 2024. PMID: 38578306
Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group.
Müller K, Schlamann A, Guckenberger M, Warmuth-Metz M, Glück A, Pietschmann S, Wawer A, Kortmann RD, Kramm C, von Bueren AO. Müller K, et al. Among authors: von bueren ao. Strahlenther Onkol. 2014 Apr;190(4):377-81. doi: 10.1007/s00066-013-0513-0. Epub 2014 Feb 19. Strahlenther Onkol. 2014. PMID: 24638239
Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome.
Völkl S, Rensing-Ehl A, Allgäuer A, Schreiner E, Lorenz MR, Rohr J, Klemann C, Fuchs I, Schuster V, von Bueren AO, Naumann-Bartsch N, Gambineri E, Siepermann K, Kobbe R, Nathrath M, Arkwright PD, Miano M, Stachel KD, Metzler M, Schwarz K, Kremer AN, Speckmann C, Ehl S, Mackensen A. Völkl S, et al. Among authors: von bueren ao. Blood. 2016 Jul 14;128(2):227-38. doi: 10.1182/blood-2015-11-685024. Epub 2016 Apr 20. Blood. 2016. PMID: 27099149 Free article. Clinical Trial.
Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91.
Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F, Warmuth-Metz M, Soerensen N, Emser A, Bode U, Mittler U, Urban C, Benesch M, Kortmann RD, Schlegel PG, Kuehl J, Pietsch T, Grotzer M. Rutkowski S, et al. Clin Cancer Res. 2007 May 1;13(9):2651-7. doi: 10.1158/1078-0432.CCR-06-1779. Clin Cancer Res. 2007. PMID: 17473196 Clinical Trial.
Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma.
Grotzer MA, von Hoff K, von Bueren AO, Shalaby T, Hartmann W, Warmuth-Metz M, Emser A, Kortmann RD, Kuehl J, Pietsch T, Rutkowski S. Grotzer MA, et al. Among authors: von bueren ao, von hoff k. Klin Padiatr. 2007 Nov-Dec;219(6):312-7. doi: 10.1055/s-2007-985843. Klin Padiatr. 2007. PMID: 18050040
Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.
Faoro D, von Bueren AO, Shalaby T, Sciuscio D, Hürlimann ML, Arnold L, Gerber NU, Haybaeck J, Mittelbronn M, Rutkowski S, Hegi M, Grotzer MA. Faoro D, et al. Among authors: von bueren ao. J Neurooncol. 2011 May;103(1):59-69. doi: 10.1007/s11060-010-0366-7. Epub 2010 Sep 5. J Neurooncol. 2011. PMID: 20820873 Free article.
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik AE, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor MD, Tabori U, Lichter P, Korshunov A, Pfister SM. Pfaff E, et al. Among authors: von bueren ao, von deimling a. J Clin Oncol. 2010 Dec 10;28(35):5188-96. doi: 10.1200/JCO.2010.31.1670. Epub 2010 Nov 8. J Clin Oncol. 2010. PMID: 21060032
135 results